이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Grand Pharmaceutical Group 대차 대조표 상태
재무 상태 기준 확인 6/6
Grand Pharmaceutical Group 의 총 주주 지분은 HK$15.3B 이고 총 부채는 HK$3.3B, 이는 부채 대 자기자본 비율을 21.7% 로 가져옵니다. 총자산과 총부채는 각각 HK$22.5B 및 HK$7.2B 입니다. Grand Pharmaceutical Group 의 EBIT는 HK$2.9B 이며 이자보상배율은 14.5 입니다. HK$3.3B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
21.7%
부채 비율
HK$3.31b
부채
| 이자 보상 비율 | 14.5x |
| 현금 | HK$3.32b |
| 주식 | HK$15.27b |
| 총 부채 | HK$7.24b |
| 총 자산 | HK$22.52b |
최근 재무 상태 업데이트
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Recent updates
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt
Apr 26Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)
Apr 08Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching
Mar 24재무 상태 분석
단기부채: 512 의 단기 자산 ( HK$7.0B )이 단기 부채( HK$5.7B ).
장기 부채: 512 의 단기 자산( HK$7.0B )이 장기 부채( HK$1.5B ).
부채 대 자본 내역 및 분석
부채 수준: 512 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: 512 의 부채 대 자기자본 비율은 지난 5년간 34.6% 에서 21.7% 로 감소했습니다.
부채 범위: 512 의 부채는 영업 현금 흐름 ( 73.3% )에 의해 잘 충당되었습니다.
이자 보장: 512 의 부채에 대한 이자 지급은 EBIT( 14.5 x 적용 범위)로 잘 충당됩니다.